- Home
- VCYT vs CPRI Comparison
VCYT vs CPRI Comparison
Compare VCYT & CPRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VCYT | CPRI |
|---|---|---|
| Founded | 2006 | 1981 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.2B |
| IPO Year | 2013 | 2011 |
Fundamental Metrics
Financial Performance| Metric | VCYT | CPRI |
|---|---|---|
| Price | $41.73 | $24.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $46.00 | $26.67 |
| AVG Volume (30 Days) | 670.0K | ★ 2.0M |
| Earning Date | 02-23-2026 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | $495,141,000.00 | ★ $4,369,000,000.00 |
| Revenue This Year | $16.46 | N/A |
| Revenue Next Year | $11.37 | $2.07 |
| P/E Ratio | $109.27 | ★ N/A |
| Revenue Growth | ★ 16.41 | N/A |
| 52 Week Low | $22.61 | $11.86 |
| 52 Week High | $50.71 | $28.27 |
Technical Indicators
Market Signals| Indicator | VCYT | CPRI |
|---|---|---|
| Relative Strength Index (RSI) | 44.88 | 42.73 |
| Support Level | $40.29 | $24.97 |
| Resistance Level | $44.59 | $26.33 |
| Average True Range (ATR) | 1.69 | 0.86 |
| MACD | -0.27 | -0.12 |
| Stochastic Oscillator | 20.42 | 7.97 |
Price Performance
Historical ComparisonAbout VCYT Veracyte Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
About CPRI Capri Holdings Limited
Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. Capri also owns a third brand, Versace, but has agreed to sell it to Prada. John Idol has served as Capri's CEO since 2003.